Deferiprone (Standard)
Based on 1 Customer Validation
Deferiprone (Standard) is the analytical standard of Deferiprone. This product is intended for research and analytical applications. Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study.
For research use only. We do not sell to patients.
- Purity: 99.99%
- CAS No.: 30652-11-0
- Formula: C₇H₉NO₂
- Molecular Weight:139.15
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 30652-11-0
-
Appearance Solid
-
Molecular Weight 139.15
-
Formula C₇H₉NO₂
-
Color White to off-white
-
SMILES
O=C1C(O)=C(C)N(C)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rui V. Simões, Inhibition of prostate cancer proliferation by Deferiprone. NMR Biomed [Content Brief]
[2]. Oded Shalev. et al. Deferiprone (L1) Chelates Pathologic Iron Deposits From Membranes of Intact Thalassemic and Sickle Red Blood Cells Both In Vitro and In Vivo. [Content Brief]
[3]. Ngan Thi Tran, et al. Antiplatelet activity of deferiprone through cyclooxygenase-1 inhibition. Platelets 2020 May 18;31(4):505-512. [Content Brief]
[4]. Andrea Pagani, MD, et al. Deferiprone Stimulates Aged Dermal Fibroblasts via HIF-1α Modulation.Pathog Dis. 2018 Jul 1;76(5). [Content Brief]
[5]. Débora C Coraça-Huber, et al. Iron chelation destabilizes bacterial biofilms and potentiates the antimicrobial activity of antibiotics against coagulase-negative Staphylococci. Pathogens and Disease, Volume 76, Issue 5, July 2018, fty052 [Content Brief]
[6]. Shalini S. Rao, et al. Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology. Neurotherapeutics. 2021 Apr;18(2):1081-1094. [Content Brief]
[7]. Makhdoumi P, et al. Oral deferiprone administration ameliorates cisplatin-induced nephrotoxicity in rats.J Pharm Pharmacol. 2018 Oct;70(10):1357-1368. [Content Brief]
[8]. Yanan Zhang, et al. Taurine and deferiprone against Al-linked apoptosis in rat hippocampus. J Trace Elem Med Biol. 2023 Mar;76:127113. [Content Brief]
[9]. Kontoghiorghes GJ, et al. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf. 2003;26(8):553-584. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz